Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NELARABINE vs AGRYLIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nelarabine is a prodrug of ara-G, a deoxyguanosine analog. It is converted to ara-GTP, which accumulates in T-cells and inhibits DNA synthesis, leading to cell death.
Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.
T-cell acute lymphoblastic leukemia (T-ALL),T-cell lymphoblastic lymphoma (T-LBL),Relapsed or refractory T-ALL/T-LBL
Essential thrombocythemia (ET) to reduce elevated platelet counts and the risk of thrombotic complications
1500 mg/m2 intravenously over 2 hours on days 1, 3, and 5, repeated every 28 days.
Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.
Terminal t1/2: 30 hours (range 21-48 h) in adults; prolonged in renal impairment. Ara-G (active metabolite) t1/2: 3 hours.
Terminal elimination half-life: 1.3–1.5 days (31–36 hours) in patients with ET; allows twice-daily dosing.
Nelarabine is demethylated by adenosine deaminase (ADA) to ara-G, which is then phosphorylated to ara-GTP intracellularly. It is partially metabolized by aldehyde oxidase.
Primarily metabolized by CYP1A2 to the active metabolite 3-hydroxyanagrelide, and to a lesser extent by CYP2C19 and CYP2D6.
Renal: 50-60% as unchanged ara-G; fecal: <5% as metabolites; biliary: negligible.
Renal: 80% (primarily unchanged drug), Biliary/Fecal: 5%
<25% bound to plasma proteins (albumin).
82–88% bound to plasma proteins (primarily albumin).
Vd: 197 L/m² (approx 5.6 L/kg based on 1.73 m²/70 kg), indicating extensive tissue distribution.
30–36 L (approximately 0.45–0.5 L/kg for a 70 kg adult); indicates extensive tissue distribution.
IV only; oral bioavailability not established (<5% due to extensive first-pass metabolism).
Oral: 65–80% (median 73%)
Cr Cl 30-60 m L/min: reduce dose to 975 mg/m2. Cr Cl <30 m L/min: not recommended.
No specific GFR-based recommendations; use with caution in renal impairment (Cr Cl <50 m L/min) and monitor closely.
Child-Pugh Class B or C: reduce dose to 975 mg/m2. No data for severe impairment.
Child-Pugh A: No adjustment. Child-Pugh B or C: Reduce initial dose by 50% and titrate cautiously.
650 mg/m2 intravenously over 1 hour daily for 5 consecutive days, repeated every 21 days.
Children ≥7 years: 0.5 mg orally once or twice daily; adjust based on platelet response. Maximum: 10 mg/day. Not established for <7 years.
No specific dose adjustment recommended; monitor renal function and hematologic toxicity closely.
No specific adjustment; start at lower end of dosing range (0.5 mg twice daily) and monitor renal function and platelet counts closely.
Severe neurotoxicity, including Guillain-Barré-like syndrome, peripheral neuropathy, and CNS demyelination. Avoid in patients with severe pre-existing neurological conditions.
None
Monitor for neurological toxicity; may require discontinuation.,Hematologic toxicity: neutropenia, thrombocytopenia, anemia.,Increased risk of infection.,Tumor lysis syndrome prophylaxis required.,Hepatotoxicity and renal toxicity.
Cardiovascular risks: increased risk of ventricular tachycardia, QTc prolongation, and heart failure; use caution in patients with known cardiac disease.,Hematologic effects: monitor complete blood counts regularly due to risk of anemia, leukopenia, or thrombocytopenia.,Hepatic impairment: reduce dose in patients with moderate to severe hepatic impairment.,Renal impairment: use with caution in severe renal impairment.
Hypersensitivity to nelarabine or its components.,Severe pre-existing neurological disorders (e.g., Guillain-Barré syndrome, peripheral neuropathy).,Pregnancy (may cause fetal harm).
Severe hepatic impairment,Known hypersensitivity to anagrelide or any component of the formulation
No known food interactions. Maintain adequate hydration to prevent tumor lysis syndrome. Avoid grapefruit juice? No evidence for interaction.
Grapefruit and grapefruit juice should be avoided as they may increase anagrelide plasma concentrations. No other specific dietary restrictions; however, maintain adequate hydration to reduce risk of crystalluria.
Nelarabine is embryotoxic and fetotoxic in animal studies. It is classified as FDA Pregnancy Category D. There is evidence of fetal harm in pregnant women, including increased risk of congenital malformations, intrauterine growth restriction, and fetal death. Use during the first trimester carries highest risk of major malformations; second and third trimester exposure may cause myelosuppression and low birth weight. Avoid in pregnancy unless benefit outweighs risk.
Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies) at doses less than the human therapeutic dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. First trimester: Avoid due to organogenesis risk. Second and third trimesters: Unknown risks; consider alternative therapy.
No human data on nelarabine excretion in breast milk. Due to its mechanism of action (DNA synthesis inhibition) and potential for serious adverse effects in the nursing infant, breastfeeding is contraindicated during therapy and for at least 3 months after the last dose.
It is not known whether anagrelide is excreted in human milk. No M/P ratio is available. Due to potential for serious adverse reactions in breastfed infants (e.g., thrombocytopenia, cardiovascular effects), advise women not to breastfeed during treatment and for at least 7 days after last dose.
No established dose adjustments in pregnancy. Physiological changes in pregnancy (increased plasma volume, renal clearance, hepatic metabolism) may alter nelarabine pharmacokinetics, but no specific studies exist. Use standard weight-based dosing with careful monitoring for toxicity. Consider reducing dose if severe myelosuppression or neurotoxicity occurs.
No specific pharmacokinetic studies in pregnancy. Pregnancy-induced plasma volume expansion may lower drug concentrations, potentially requiring dose adjustment to maintain therapeutic effect. However, due to teratogenicity risks, avoid use in pregnancy. If necessary, start at lowest effective dose (0.5 mg/day) and titrate based on platelet count monitoring, not to exceed 10 mg/day.
Administer intravenously over 2 hours. Monitor for neurological toxicity including somnolence, ataxia, and seizures. Premedicate with antiemetics. Use in T-cell acute lymphoblastic leukemia/lymphoma after failure of two prior regimens. Contraindicated in severe renal impairment (Cr Cl <30 m L/min).
Agrylin (anagrelide) is a phosphodiesterase III inhibitor used to reduce platelet counts in essential thrombocythemia. Monitor platelet count weekly during titration; target <600,000/µL. Avoid in patients with severe hepatic impairment (Child-Pugh C). Use with caution in cardiac disease due to risk of QT prolongation and arrhythmias. Anagrelide may increase bleeding risk, especially when combined with anticoagulants or NSAIDs. Discontinue 4-5 days before elective surgery.
This drug can cause severe drowsiness and coordination problems; do not drive or operate machinery until you know how it affects you.,Report any unusual tiredness, muscle weakness, or tingling in hands/feet to your doctor immediately.,If you experience seizures, loss of consciousness, or confusion, seek emergency medical attention.,You will have regular blood tests to monitor your blood cell counts and kidney function.,This drug can cause serious infections; wash hands frequently and avoid crowds.,Use effective contraception during treatment and for at least 3 months after stopping.,Do not receive live vaccines during therapy without consulting your doctor.
Take exactly as prescribed; do not skip doses or double up.,Report any signs of bleeding (easy bruising, nosebleeds, black/tarry stools) or palpitations immediately.,Avoid NSAIDs like ibuprofen and aspirin unless directed by your doctor.,Do not consume grapefruit or grapefruit juice while taking this medication.,Inform all healthcare providers (including dentists) that you are on anagrelide.,Store at room temperature away from moisture and heat.
"Roflumilast may increase the immunosuppressive activities of Nelarabine."
"The risk or severity of adverse effects can be increased when Docetaxel is combined with Nelarabine."
"Nelarabine may decrease the cardiotoxic activities of Acetyldigitoxin."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NELARABINE vs AGRYLIN, answered by our medical review team.
NELARABINE is a Antineoplastic Agent that works by Nelarabine is a prodrug of ara-G, a deoxyguanosine analog. It is converted to ara-GTP, which accumulates in T-cells and inhibits DNA synthesis, leading to cell death.. AGRYLIN is a Antineoplastic Agent that works by Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NELARABINE and AGRYLIN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NELARABINE is: 1500 mg/m2 intravenously over 2 hours on days 1, 3, and 5, repeated every 28 days.. The standard adult dose of AGRYLIN is: Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NELARABINE and AGRYLIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NELARABINE is classified as Category C. Nelarabine is embryotoxic and fetotoxic in animal studies. It is classified as FDA Pregnancy Category D. There is evidence of fetal harm in pregnant women, including increased risk. AGRYLIN is classified as Category C. Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.